Turnstone Biologics Statistics
Total Valuation
TSBX has a market cap or net worth of $54.81 million. The enterprise value is -$20.43 million.
| Market Cap | 54.81M |
| Enterprise Value | -20.43M |
Important Dates
The next estimated earnings date is Friday, August 30, 2024, after market close.
| Earnings Date | Aug 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TSBX has 23.13 million shares outstanding. The number of shares has increased by 725.97% in one year.
| Shares Outstanding | 23.13M |
| Shares Change (YoY) | +725.97% |
| Shares Change (QoQ) | +99.01% |
| Owned by Insiders (%) | 3.83% |
| Owned by Institutions (%) | 67.71% |
| Float | 14.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.72, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.72 |
| Quick Ratio | n/a |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -174.30% and return on invested capital (ROIC) is -95.89%.
| Return on Equity (ROE) | -174.30% |
| Return on Assets (ROA) | -72.50% |
| Return on Capital (ROIC) | -95.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$936,450 |
| Employee Count | 80 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -188,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 2.75 |
| Relative Strength Index (RSI) | 41.91 |
| Average Volume (20 Days) | 171,600 |
Short Selling Information
The latest short interest is 519,171, so 2.24% of the outstanding shares have been sold short.
| Short Interest | 519,171 |
| Short Previous Month | 653,380 |
| Short % of Shares Out | 2.24% |
| Short % of Float | 3.70% |
| Short Ratio (days to cover) | 4.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -79.33M |
| Pretax Income | -75.09M |
| Net Income | -74.92M |
| EBITDA | -72.49M |
| EBIT | -75.09M |
| Earnings Per Share (EPS) | -$9.17 |
Balance Sheet
The company has $77.96 million in cash and $2.72 million in debt, giving a net cash position of $75.25 million or $3.25 per share.
| Cash & Cash Equivalents | 77.96M |
| Total Debt | 2.72M |
| Net Cash | 75.25M |
| Net Cash Per Share | $3.25 |
| Equity (Book Value) | 80.01M |
| Book Value Per Share | 3.46 |
| Working Capital | 72.34M |
Cash Flow
In the last 12 months, operating cash flow was -$66.44 million and capital expenditures -$191,000, giving a free cash flow of -$66.63 million.
| Operating Cash Flow | -66.44M |
| Capital Expenditures | -191,000 |
| Free Cash Flow | -66.63M |
| FCF Per Share | -$2.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TSBX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -725.97% |
| Shareholder Yield | -725.97% |
| Earnings Yield | -136.67% |
| FCF Yield | -121.56% |
Analyst Forecast
The average price target for TSBX is $19.00, which is 701.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 701.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |